Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Rhea-AI Summary

Halozyme (NASDAQ: HALO) named David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay will oversee all financial operations while the company continues its search for a permanent CFO.

He brings more than 30 years of biotech financial leadership and previously served as Halozyme CFO from 2003–2009 and 2013–2015. Halozyme has engaged a leading executive search firm to identify a permanent CFO; Ramsay will remain until an appointment is made.

Positive

• Interim CFO start date set for March 23, 2026
• 30+ years of sector finance experience in biotechnology and life sciences
• Prior Halozyme CFO experience 2003–2009 and 2013–2015

Negative

• Company currently without a permanent CFO until search completes
• Interim appointment may imply short‑term leadership uncertainty for investors

Key Figures

CFO start date: March 23, 2026 Leadership experience: More than 30 years Prior CFO tenure: 2003–2009 +2 more

5 metrics

CFO start date March 23, 2026 Effective date for David Ramsay as Interim CFO

Leadership experience More than 30 years Strategic financial leadership across biotech and life sciences

Prior CFO tenure 2003–2009 First period serving as Halozyme’s Chief Financial Officer

Prior CFO tenure 2013–2015 Second period serving as Halozyme’s Chief Financial Officer

Bonti sale date October 2018 Month and year Bonti, Inc. was sold to Allergan plc

Market Reality Check

Price: $66.48 Vol: Volume 1,531,982 is 0.77x...

normal vol

$66.48 Last Close

Volume Volume 1,531,982 is 0.77x the 20-day average of 1,980,637, indicating subdued trading activity pre-announcement. normal

Technical Shares at $66.48 were trading slightly below the 200-day MA of $66.57, and about 19.14% under the 52-week high of $82.22.

Peers on Argus

With HALO down 1.96% and only one peer (CORT) in the momentum scanner moving up,...

1 Up

With HALO down 1.96% and only one peer (CORT) in the momentum scanner moving up, pre-news trading pointed to a stock-specific drift rather than a coordinated biotech-sector move.

Historical Context

5 past events · Latest: Mar 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Regulatory approval	Positive	+0.0%	FDA approval for TECVAYLI plus DARZALEX FASPRO in multiple myeloma.
Feb 25	Investor conferences	Neutral	-0.0%	Participation in multiple upcoming investor conferences and webcasts.
Feb 17	Earnings results	Positive	-9.0%	Record 2025 revenue, strong royalty growth, reiterated 2026 guidance.
Feb 10	Earnings date	Neutral	-0.9%	Announcement of timing and webcast details for 2025 results.
Jan 28	Guidance raise	Positive	+3.7%	Raised 2025–2026 revenue and royalty guidance and Surf Bio acquisition.

Pattern Detected

Recent fundamental and regulatory catalysts, including strong guidance and an FDA approval, have produced mixed and sometimes muted price reactions, with one notable selloff on record revenue guidance.

Recent Company History

Over the last few months, Halozyme has reported several significant developments. On Jan 28, it raised 2025–2026 revenue and royalty guidance and closed the Surf Bio acquisition, with shares rising 3.72%. On Feb 17, it posted record 2025 revenue of $1.397B and reiterated strong 2026 guidance but the stock fell 9.01%. A subsequent FDA approval-related update on Mar 6 moved the stock only 0.01%. Against this backdrop, the interim CFO appointment fits into an already active corporate period.

Market Pulse Summary

This announcement highlights a leadership transition in Halozyme’s finance function, with David Rams...

Analysis

This announcement highlights a leadership transition in Halozyme’s finance function, with David Ramsay returning as Interim CFO effective March 23, 2026. His prior tenures from 2003–2009 and 2013–2015 and more than 30 years of sector experience suggest continuity and familiarity with the company’s growth path. Investors may watch for updates on the search for a permanent CFO, future guidance commentary, and how the finance team supports ongoing strategic and commercialization initiatives.

Key Terms

capital markets, corporate finance, investor relations

3 terms

capital markets financial

"including extensive experience in capital markets, corporate finance, investor relations"

Capital markets are places where people and organizations buy and sell long-term investments like stocks and bonds. They help connect those who need money to grow or fund projects with investors looking to earn returns over time. For investors, capital markets are important because they offer opportunities to invest, save, and grow their wealth through a variety of financial assets.

corporate finance financial

"including extensive experience in capital markets, corporate finance, investor relations"

Corporate finance is the set of decisions a company makes about getting and using money—how it raises funds, where it spends them, and how it manages cash and risk. For investors, these choices determine a company’s ability to grow, pay dividends or buy back shares, and survive downturns; think of it as a household’s budgeting and borrowing plan that signals whether the business is living within its means and planning for the future.

investor relations financial

"including extensive experience in capital markets, corporate finance, investor relations"

Investor relations is the communication process between a company and its current or potential investors. It involves sharing information about the company's performance, strategies, and outlook to help investors make informed decisions. Effective investor relations build trust and transparency, similar to a clear conversation between a business and someone considering investing, ensuring both parties understand each other's interests and expectations.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO.

Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale‑up. He previously served as Halozyme's Chief Financial Officer from 2003 to 2009 and again from 2013 to 2015, during which time the company evolved from a private enterprise to a billion‑dollar public biopharmaceutical company.

During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme's foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018.

"I am thrilled to have the opportunity to work with David again," said Dr. Helen Torley, President and Chief Executive Officer. "His deep understanding of Halozyme, combined with his exceptional capital markets expertise, investor expertise and credibility, and his longstanding record of financial leadership, makes him an invaluable partner as we advance our strategic priorities. David has made a lasting impact on Halozyme's evolution, and we are fortunate to welcome him back into a role where his experience and leadership will be immediately impactful."

The company's executive search for a permanent Chief Financial Officer is well underway and progressing. Halozyme has engaged a leading executive search firm to identify candidates who bring the combination of capital markets expertise and strategy. Mr. Ramsay will remain in the role until a permanent CFO is appointed.

Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE^® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^® and XYOSTED^®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding Halozyme's executive search efforts for a permanent chief executive officer, future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including potential delays in hiring a permanent chief financial officer. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-david-ramsay-as-interim-chief-financial-officer-302711900.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

Who is the interim CFO of Halozyme (HALO) and when does he start?

David Ramsay is interim CFO and will assume the role effective March 23, 2026. According to the company, he will oversee all financial operations during the ongoing search for a permanent CFO.

What is David Ramsay's experience relevant to his role as Halozyme (HALO) interim CFO?

Ramsay has more than 30 years of financial leadership in biotech and life sciences. According to the company, he was Halozyme CFO in 2003–2009 and 2013–2015, and has capital markets and operational scale‑up experience.

How long will David Ramsay serve as interim CFO for Halozyme (HALO)?

Ramsay will serve as interim CFO until a permanent CFO is appointed. According to the company, an executive search is underway and he will remain in the role during that process.

What does Halozyme (HALO) say about the search for a permanent CFO?

Halozyme has engaged a leading executive search firm to identify candidates with capital markets expertise and strategy experience. According to the company, the search is active and progressing.

Will David Ramsay's interim appointment affect Halozyme (HALO) financial operations?

The company expects Ramsay to oversee all financial operations during the interim period. According to the company, his prior Halozyme CFO experience should enable immediate oversight and continuity.